380389-67-3

Basic information

• Product Name: AKOS B033328
• Synonyms: AKOS B033328;CHEMBRDG-BB 4022627;2-(1H-Imidazol-1-yl)-5-(trifluoromethyl)aniline;2-IMIDAZOL-1-YL-5-TRIFLUOROMETHYL-PHENYLAMINE;AKOS BBV-008277;ALINDA 16701;ART-CHEM-BB B033328;UKRORGSYN-BB BBV-008277
• CAS NO: 380389-67-3
• Molecular Formula: C₁₀H₈F₃N₃
• Molecular Weight: 227.19
• Mol File: 380389-67-3.mol

Chemical Properties

• Boiling Point: 336.2°C at 760 mmHg
• Flash Point: 157.1°C
• Appearance: /
• Density: 1.39g/cm³
• Vapor Pressure: 0.000114mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: AKOS B033328(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS B033328(380389-67-3)
• EPA Substance Registry System: AKOS B033328(380389-67-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 380389-67-3(Hazardous Substances Data)

Usage

Uses

Used in Cosmetics Industry:
AKOS B033328 is used as a UV filter for its ability to absorb and dissipate UV radiation, providing protection against harmful ultraviolet rays in sunscreens and other cosmetic products.
Used in Pharmaceutical Industry:
AKOS B033328 is used as an active pharmaceutical ingredient in the development of medications due to its potential therapeutic properties.
It is important to handle AKOS B033328 with care, as it is classified as a harmful substance and may cause irritation to the skin and eyes.

InChI:InChI=1/C10H8F3N3/c11-10(12,13)7-1-2-9(8(14)5-7)16-4-3-15-6-16/h1-6H,14H2

Upstream product

• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 

Downstream Products

• 1060673-62-2 3-({1-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-7-(trifluoromethyl)imidazo[1,2-a]quinoxalin-4-yl}amino)propan-1-ol 
• 1060673-28-0 N-{3-[4-(3-Hydroxy-propylamino)-7-trifluoromethyl-imidazo[1,2-a]quinoxalin-1-yl]-phenyl}-acetamide 
• 1060673-29-1 3-{4-[(3-hydroxypropyl)amino]-7-(trifluoromethyl)imidazo[1,2-a]quinoxalin-1-yl}benzenesulfonamide 
• 1060673-31-5 3-{[1-(4-methoxyphenyl)-7-(trifluoromethyl)imidazo[1,2-a]quinoxalin-4-yl]amino}propan-1-ol 
• 380389-65-1 1-(4-chlorophenylcarboxamido)-2-(1H-1-imidazolyl)-5-trifluoromethylbenzene 
• 380420-01-9 5-(4-chlorobenzoyl)-4-morpholino-4-thioxo-7-trifluoromethyl-4,5-dihydrobenzo[e]imidazo[2,1-c][1,4,2]diazaphosphinine 
• 420849-29-2 5-(4-chlorobenzoyl)-4-phenyl-7-trifluoromethyl-4,5-dihydrobenzo[e]imidazo[2,1-c][1,4,2]diazaphosphinine 
• 420849-27-0 5-(4-chlorobenzoyl)-4-bromo-7-trifluoromethyl-4,5-dihydrobenzo[e]imidazo[2,1-c][1,4,2]diazaphosphinine 

Relevant articles and documents

A catalytic intramolecular nitrene insertion into a copper(i)-N-heterocyclic carbene bond yielding fused nitrogen heterocycles

N-(2-Azidophenyl)azolium salts were easily prepared and reacted with copper(i) under conditions allowing the formation of NHC complexes. Under these conditions, the formation of benzimidazo-fused heterocycles occurred under catalytic, efficient and very mild conditions. This reaction is proposed to proceed via dinitrogen elimination and imido/nitrene-NHC cyclization.

New imidazolo-heteroaryl derivatives with antibacterial properties

The invention relates to Imidazolo-heteroaryl derivatives of formula (I) The compounds inhibit the activity of the Dlta enzyme of Gram-positive bacteria and are useful to treat Gram-positive bacterial infections. Furthermore the application discloses method for assessing the Dlta inhibitory activity of tested molecules and a method for measuring the efficacy of molecules in inhibiting bacteria proliferation in vitro.

N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES

The present invention relates to heterocyclic substituted N-Oxides of formula (I), the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS

The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Synthesis and properties of 4,5-dihydrobenzo[e]imidazo[2,1-c][1,4,2]diazaphosphinine derivatives

A number of 4,5-dihydrobenzo[e]imidazo[2,1-c][1,4,2]diazaphosphinine derivatives were prepared by the direct phosphorylation of 1-(4-Chloro-phenylcarboxamido)-2-(1H-1-imidazolyl)-5-trifluoromethylbenzene in basic medium with phosphorus(III) bromide and dibromophenylphosphine. The amide was reacted with phosphorus(III) bromide to yield the tricyclic compound. The tricyclic compound with a trivalent phosphorus atom went through the diazaphosphine ring opening upon treatment with secondary amines in the presence of sulphur.